A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency

Bibliography

• About Psoriasis Statistics. Available from: http://www.psoriasis.org/netcommunity/learn/about-psoriasis/statistics 2010; 7-31-2010
   Google Scholar
• Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004;45:155-9
   PubMedGoogle Scholar
• Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life and stigmatization. Physiol Behav 2000;70:567-71
   PubMed Web of Science ®Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000;80:430-4
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Fowler JF, Duh MS, Rovba L, The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008;59:772-80
   PubMed Web of Science ®Google Scholar
• Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol 2010;146:46-54
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-84
   PubMed Web of Science ®Google Scholar
• Sizto S, Bansback N, Feldman SR, Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009;160:1264-72
   PubMed Web of Science ®Google Scholar
• Olivieri I, de Portu S, Salvarani C, The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 2008;47:1664-70
   PubMed Web of Science ®Google Scholar
• Bansback N, Sizto S, Sun H, Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009;219:209-18
   PubMed Web of Science ®Google Scholar
• Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother 2006;7:157-67
   PubMed Web of Science ®Google Scholar
• Nelson AA, Pearce DJ, Fleischer AB Jr, Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol 2008;58:125-35
   PubMed Web of Science ®Google Scholar
• Feldman SR, Garton R, Averett W, Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother 2003;4:1525-33
   PubMed Web of Science ®Google Scholar
• Brimhall AK, King LN, Licciardone JC, Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:274-85
   PubMed Web of Science ®Google Scholar
• Schmitt J, Zhang Z, Wozel G, Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:513-26
   PubMed Web of Science ®Google Scholar
• Feldman S. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. National Psoriasis Foundation; Portland, OR: 2005
   Google Scholar
• Food and Drug Administration. FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149561.htm 2010; 8-10-2010
   Google Scholar
• Griffiths CE, Clark CM, Chalmers RJ, A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1-125
   PubMedGoogle Scholar
• Heydendael VM, Spuls PI, Opmeer BC, Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65
   PubMed Web of Science ®Google Scholar
• Grossman RM, Chevret S, Abi-Rached J, Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996;132:623-9
   PubMedGoogle Scholar
• Zachariae H, Kragballe K, Hansen HE, Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997;136:531-5
   PubMed Web of Science ®Google Scholar
• Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999;41:S25-8
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66
   PubMed Web of Science ®Google Scholar
• Roenigk HH Jr, Auerbach R, Maibach H, Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85
   PubMed Web of Science ®Google Scholar
• Krutmann J. Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy. J Photochem Photobiol B 1998;44:159-64
   Google Scholar
• Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol 2003;49:S78-86
   PubMed Web of Science ®Google Scholar
• Coven TR, Burack LH, Gilleaudeau R, Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 1997;133:1514-22
   PubMed Web of Science ®Google Scholar
• van Weelden H, De La Faille HB, Young E, van der Leun JC. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988;119:11-19
   PubMed Web of Science ®Google Scholar
• Walters IB, Burack LH, Coven TR, Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999;40:893-900
   PubMed Web of Science ®Google Scholar
• Koek MB, Buskens E, van Weelden H, Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). BMJ 2009;338:b1542
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Prystowsky JH, Bourget T, Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591-4
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Acitretin in combination with UVB or PUVA. J Am Acad Dermatol. 1999;41:S22-4
   Google Scholar
• Ashcroft DM, Li Wan PA, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000;25:1-10
   PubMed Web of Science ®Google Scholar
• Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol 2002;46:557-9
   PubMed Web of Science ®Google Scholar
• Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis. Manag Care Interface 2006;19:33-6; 39
   PubMedGoogle Scholar
• Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999;41:728-32
   PubMed Web of Science ®Google Scholar
• Sivanesan SP, Gattu S, Hong J, Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. J Am Acad Dermatol 2009;61:793-8
   PubMed Web of Science ®Google Scholar
• Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997;336:1041-5
   PubMed Web of Science ®Google Scholar
• Stern RS. Carcinogenic risk of psoralen plus ultraviolet radiation therapy: evidence in humans. Natl Cancer Inst Monogr 1984;66:211-16
   PubMedGoogle Scholar
• Lindelof B, Sigurgeirsson B, Tegner E, PUVA and cancer: a large-scale epidemiological study. Lancet 1991;338:91-3
   PubMed Web of Science ®Google Scholar
• Stern RS, Bolshakov S, Nataraj AJ. Ananthaswamy HN: p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization. J Invest Dermatol 2002;119:522-6
   PubMed Web of Science ®Google Scholar
• Papp KA. Potential future therapies for psoriasis. Semin Cutan Med Surg 2005;24:58-63
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Abuabara K, Shin DB, The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64(6):1035-50
   PubMed Web of Science ®Google Scholar
• Wyeth. Enbrel (etanercept). Available from: http://www.enbrel.com/documents/ENBREL-Prescribing-Information.pdf 2009; 8-11-2010
   Google Scholar
• Centocor Ortho Biotech, Inc. Remicade (infliximab). Available from: http://www.remicade.com/remicade/assets/HCP_PPI.pdf 2009; 8-11-2010
   Google Scholar
• Abbott. Humira (adalimumab). Available from: http://rxabbott.com/pdf/humira.pdf 2009; 8-11-2010
   Google Scholar
• Leonardi CL, Powers JL, Matheson RT, Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de KP, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28
   PubMed Web of Science ®Google Scholar
• Koo J, Lee E, Lee CS, Lebwohl M. Psoriasis. J Am Acad Dermatol 2004;50:613-22
   PubMedGoogle Scholar
• Kwon HJ, Cote TR, Cuffe MS, Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11
   PubMed Web of Science ®Google Scholar
• Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol 2004;151:3-15
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9
   PubMed Web of Science ®Google Scholar
• Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9
   PubMed Web of Science ®Google Scholar
• Gordon KB, Bonish BK, Patel T, The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005;153:945-53
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
   PubMed Web of Science ®Google Scholar
• Menter A, Cather JC, Baker D, The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006;54:61-3
   PubMed Web of Science ®Google Scholar
• Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 2005;38:75-87
   PubMed Web of Science ®Google Scholar
• Langley R. Long-term safety and efficacy of adalimumab in the treatment ofmoderate to severe chronic plaque psoriasis. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology; New Orleans, LA.2005
   Google Scholar
• Abbott Laboratories. Humira (adalimumab) package insert. North Chicago, IL; 2004
   Google Scholar
• Biogen, Inc. Amevive (alefacept) prescribing information. Cambridge, MA; 2005
   Google Scholar
• Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003;49:S87-97
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Lebwohl M, Em GC. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003;13:117-23
   PubMed Web of Science ®Google Scholar
• Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005;24:37-45
   PubMed Web of Science ®Google Scholar
• Goffe B, Papp K, Gratton D, An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005;27:1912-21
   PubMed Web of Science ®Google Scholar
• Torti DC, Feldman SR. Interleukin-12, interleukin-23 and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-68
   PubMed Web of Science ®Google Scholar
• Kauffman CL, Aria N, Toichi E, A phase I study evaluating the safety, pharmacokinetics and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-14
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
   PubMed Web of Science ®Google Scholar
• Centocor Ortho Biotech, Inc. Stelara (ustekinumab). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125261s001lbl.pdf 2009; 8-10-2010
   Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
   PubMed Web of Science ®Google Scholar
• Schafer JA, Kjesbo NK, Gleason PP. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm 2010;16:402-16
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Medical Review of Ustekinumab Application number 125261. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125261s000_MedR.pdf 2010; 8-12-2010
   Google Scholar
• Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60:1001-17
   PubMed Web of Science ®Google Scholar
• Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006;4:35
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:185-91
   PubMed Web of Science ®Google Scholar
• Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003;14:158-65
   PubMedGoogle Scholar
• Krueger G, Koo J, Lebwohl M, The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-16
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649-61
   PubMed Web of Science ®Google Scholar
• Nelson AA, Pearce DJ, Fleischer AB, New treatments for psoriasis: which biologic is best? J Dermatolog Treat 2006;17:96-107
   PubMed Web of Science ®Google Scholar
• Lehman B. The red book. Houghton Mifflin Co; Boston: 2010
   Google Scholar
• Yentzer BA, Feldman SR. Trends in home phototherapy adoption in the US: monetary disincentives are only the tip of the iceberg. J Dermatolog Treat 2011;22(1):27-30
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Clinical Laboratory and Physician fee schedules. Available from: http://www.cms.hhs.gov/home/medicare/asp 2010; 7-29-2010
   Google Scholar
• American Medical Association. CPT Code Search. Available from: https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?requestid=74979 2010; 7-29-2010
   Google Scholar
• Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol 1999;141:698-702
   PubMed Web of Science ®Google Scholar
• Shikiar R, Bresnahan BW, Stone SP, Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003;1:53
   PubMedGoogle Scholar
• Mazzotti E, Picardi A, Sampogna F, Sensitivity of the dermatology life quality index to clinical change in patients with psoriasis. Br J Dermatol 2003;149:318-22
   PubMed Web of Science ®Google Scholar
• Cameron H, Yule S, Moseley H, Taking treatment to the patient: development of a home TL-01 ultraviolet B phototherapy service. Br J Dermatol 2002;147:957-65
   PubMed Web of Science ®Google Scholar
• Koek MB, Sigurdsson V, van Weelden H, Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study). BMJ 2010;340:c1490
   Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de KP, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28
   PubMed Web of Science ®Google Scholar
• Opmeer BC, Heydendael VM, De Borgie CA, Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 2004;140:685-90
   PubMed Web of Science ®Google Scholar
• Opmeer BC, Heydendael VM, De Borgie CA, Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 2004;140:685-90
   PubMed Web of Science ®Google Scholar
• Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005;24:52-7
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Thomas CG, Fleischer AB Jr, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs 2004;16:421-8; 432
   PubMedGoogle Scholar
• Feldman SR, Fleischer AB Jr, Reboussin DM, The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564-9
   PubMed Web of Science ®Google Scholar
• Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236-44
   PubMed Web of Science ®Google Scholar
• Shepard DS. Cost-effectiveness in health and medicine. In: Gold MR, Siegel JE, Russell LB and Weinstein MC (eds). New York: Oxford University Press, 1996. J Ment Health Policy Econ 1999;2:91-2
   Google Scholar
• Darst M, Reddan J. Pharmacoeconomics. In: Wolverton S. editor Comprehensive dermatologic drug therapy. Saunder; Philadelphia, PA: 2007
   Google Scholar
• Suarez-Farinas M, Shah KR, Haider AS, Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. BMC Dermatol 2010;10:1
   PubMedGoogle Scholar
• Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol Diagn Ther 2010;14:81-93
   PubMed Web of Science ®Google Scholar
• Yentzer BA, Yelverton CB, Simpson GL, Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J 2009;15:1
   PubMedGoogle Scholar
• Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol 2005;141:19-26
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drugs @ FDA. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm 2010; 7-29-2010
   Google Scholar
• Lebwohl M, Christophers E, Langley R, An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de KP, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28
   PubMed Web of Science ®Google Scholar
• Akaraphanth R, Kittipavara Y, Voravutinon N, Efficacy of a far erythemogenic dose of narrow-band ultraviolet B phototherapy in chronic plaque-type psoriasis. J Dermatol 2010;37:140-5
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Papp K, Han C, Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010;162:137-46
   PubMed Web of Science ®Google Scholar